IBEX 3519.336,80▲ +1,22%EuroStoxx 506263,26▲ +0,94%S&P 5007482,71▼ -0,28%€/$1,1438▲ +0,14%Brent76,99▼ -1,32%Bitcoin55.047▲ +1,03%

Breaking

Digi sets IPO price at €5.6 per share, aiming for €1.662 billion market capitalisationOracle amasses $638 billion in orders but its cash flow turns negativeSEPE Cancels €20,621 Debt for 52-Year-Old Subsidy RecipientMó Global Eyewear achieves HappyIndex AtWork Platinum seal for the third consecutive yearMERGE launches Startup Contest 2026 to boost Web3 startups between Europe and Latin AmericaOutlook Therapeutics Faces a Decisive July Between the FDA and Capital DilutionDigi sets IPO price at €5.6 per share, aiming for €1.662 billion market capitalisationOracle amasses $638 billion in orders but its cash flow turns negativeSEPE Cancels €20,621 Debt for 52-Year-Old Subsidy RecipientMó Global Eyewear achieves HappyIndex AtWork Platinum seal for the third consecutive yearMERGE launches Startup Contest 2026 to boost Web3 startups between Europe and Latin AmericaOutlook Therapeutics Faces a Decisive July Between the FDA and Capital Dilution

FDA

Latest fda news

1 article

Vial of medication on legal documents with a judge's gavel beside it, in a dimly lit boardroom

Companies

Outlook Therapeutics Faces a Decisive July Between the FDA and Capital Dilution

Outlook Therapeutics faces a crucial July: shareholder meeting for capital increase and FDA decision on its flagship drug. Shares rise 144% in 2026.

Beatriz Lorenzo Aguirre · 9 July 2026